Abstract:Oligomers of Amyloid-β (AβO) are deemed key in synaptotoxicity and amyloid seeding of Alzheimer's disease (AD). However, the heterogeneous and dynamic nature of AβO, and inadequate markers for AβO subtypes, have stymied effective AβO identification and therapeutic targeting in vivo. We identified an AβO-subclass epitope defined by constrained sidechain orientation of serine-asparagine-lysine (cSNK), not displayed by Aβ monomers and fibrils. Molecular dynamics simulations confirmed the epitope restriction of cSNK to AβOs. Specificity of a mouse monoclonal antibody raised against the AβO cSNK epitope was evaluated by surface plasmon resonance (SPR), dot blotting/immunoblotting, immunoprecipitation, immunohistochemistry and immunoelectron microscopy. The percent of AβO falling into the cSNK subclass was defined by acute peripheral infusion of anti-AβOcSNK in aged animals of two AD mouse models (Tg2576 and APP/PS1) followed by soluble Aβ aggregate quantification. Behavioural toxicity of AβOcSNK was evaluated in vivo by: 1) AβO intraventricularly co-injected with the anti-AbOcSNK antibody into C57BL/6 wild-type mice followed by Novel Object Recognition testing, and 2) Chronic cSNK peptide immunization of APP/PS1 mice starting at 3 months of age and continuing monthly until sacrifice at 12 months, with Cued and Contextual Fear Conditioning testing at 11 months. Immunobloting and immunohistochemistry identifed AβOcSNK sensitive cells and brain regions. A mouse monoclonal antibody targeting AβOcSNK recognizes ∼50–60 kDa SDS-resistant Aβ soluble assemblages in AD brain. Acute peripheral infusion of anti-AβOcSNK in AD mouse models reduced soluble brain Aβ aggregates by 20–30%. Chronic cSNK peptide immunization of APP/PS1 mice generated an anti-AβOcSNK IgG1 response without epitope spreading to Aβ monomers or fibrils, and was accompanied by preservation of global PSD95 expression and improved cued fear memory. The anti-AβOcSNK IgG1 reduced amygdalar plaque burdens in female mice, with no effect on hippocampal plaque. A parsimonious interpretation of the results is that antibody-accessible brain AβOcSNK, a minority of total AβO, participate in AD synaptic architectural disruption, with specific toxicity for post-synaptic dendrites, and seeding of Aβ fibrillogensis via the hippocampal-amygdala connectome. The IgG1 response indicates local neutralization/clearance, without the participation of Fc receptor-bearing cells. We demonstrate that pathogenic activities of AβO subclasses can be defined in vivo by immunological subtraction.

Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer’s disease brain

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Progress in soluble Aβ oligomers in Alzheimer's disease and drugs targeting Aβ oligomers

A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer’s brain

The Essential Role of Soluble Aβ Oligomers in Alzheimer’s Disease

Intra-membrane Oligomerization and Extra-membrane Oligomerization of Amyloid-β Peptide Are Competing Processes As a Result of Distinct Patterns of Motif Interplay

Soluble protein oligomers as emerging toxins in alzheimer's and other amyloid diseases

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression

Soluble Aβ Oligomers Impair Dipolar Heterodendritic Plasticity by Activation of mGluR in the Hippocampal CA1 Region

Aβ-oligomers: A potential therapeutic target for Alzheimer's disease

Amyloid-β oligomers increase the binding and internalization of tau oligomers in human synapses

Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies

Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology

Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease

Recent Developments in the Chemical Biology of Amyloid-Β Oligomer Targeting

Advances in targeted tracking and detection of soluble amyloid-β aggregates as a biomarker of Alzheimer's disease

An Overview of Several Inhibitors for Alzheimer's Disease: Characterization and Failure

An Updated Review of Amyloid Beta Oligomer Toxicity Inhibition and Detection for Alzheimer's Disease Diagnosis

PROPAGATIVE TOXIC Aβ OLIGOMER SUBCLASS IDENTIFIED AND DEFINED BY SOLVENT ORIENTATION OF THE LYSINE 28 SIDE CHAIN

Human Brain-Derived Aβ Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP